DBV Technologies Joins Euronext Tech Leaders Index Highlighting VIASKIN Peanut Patch Progress
DBVT•DBV Technologies was added to the Euronext Tech Leaders index effective June 22, 2026, recognizing its innovation and growth trajectory. Inclusion underscores the company’s advancement of the VIASKIN® Peanut Patch program for peanut-allergic children aged 1–7 and heightens its visibility among institutional investors.
1. Inclusion in Euronext Tech Leaders Index
DBV Technologies was officially added to the Euronext Tech Leaders index on June 22, 2026, joining over 100 high-growth companies across European markets. This placement recognizes DBV’s innovation, clinical progress and growth trajectory within the biotech sector.
2. Significance for Institutional Investors
Inclusion provides DBV with heightened exposure to institutional investors and potential passive inflows from Euronext-linked funds. The index spotlights firms demonstrating strong financial metrics, market presence and innovation, which could boost DBV’s stock liquidity and trading volume.
3. Progress of VIASKIN Peanut Patch Program
DBV is advancing its VIASKIN® Peanut Patch through late-stage clinical trials targeting peanut-allergic toddlers aged 1–3 and children aged 4–7. This epicutaneous immunotherapy approach aims to desensitize the immune system via skin delivery of allergen, with key readouts expected in upcoming quarters.
